A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it

Chemical Biology and Drug Design

Volumn 73, Issue 1, 2009, Pages 115-126

  Wang, Hui Yuan ^a,b   Li, Lin Li ^b   Cao, Zhi Xing ^a   Luo, Shi Dong ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Aurora B; Drug design; Kinase inhibitor; Pharmacophore modeling; Virtual screening

Indexed keywords

2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR;

AROMATIZATION; ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG SCREENING; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN-SERINE-THREONINE KINASES; REPRODUCIBILITY OF RESULTS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58149092997     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00751.x     Document Type: Article

References (55)

1. Matthews N., Visintin C., Hartzoulakis B., Jarvis A., Selwood D.L. (2006) Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther 6 : 109 120.
2. Marumoto T., Zhang D., Saya H. (2005) Aurora-Asa guardian of poles. Nat ReV Cancer 5 : 42 50.
3. Andrews P.D., Knato E., Moore W.J., Swedlow J.R. (2003) Mitotic mechanics: the Auroras come into view. Curr Opin Cell Biol 15 : 672 683.
4. Giet R., Prigent C. (2001) The non-catalytic domain of the Xenopus laevis Aurora A kinase localises the protein to the centrosome. J Cell Sci 114 : 2095 2104.
5. Carmena M., Earnshaw W.C. (2003) The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 4 : 842 854.
6. Bischoff J.R., Plowman G.D. (1999) The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9 : 454 459.
7. Warner S.L., Bearss D.J., Han H., Von Hoff D.D. (2003) Targeting Aurora-2 kinase in cancer. Mol Cancer Ther 2 : 589 595.
8. Goepfert T.M., Brinkley B.R. (2000) The centrosome-associated Aurora/Ipl-like kinase family. Curr Top Dev Biol 49 : 331 342.
9. Sakakura C., Hagiwara A., Yasuoka R., Fujita Y., Nakanishi M., Masuda K., Shimomura K., Nakamura Y., Inazawa J., Abe T., Yamagishi H. (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84 : 824 831.
10. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S.M., Novotny M. (1998) A homologue of Drosophila Aurora kinase is oncogenic and amplified in colorectal cancers. EMBO J 17 : 3052 3065.
11. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., Brinkley B.R., Sen S. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20 : 189 193.
12. Giet R., Prigent C. (1999) Aurora/Ipl1p-related kinases, a new family of mitotic serine-threonine kinases. J Cell Sci 112 : 3591 3601.
13. Tatsuka M., Katayama H., Ota T., Tanaka T., Odashima S., Suzuki F., Terada Y. (1998) Multinuclearity and increased ploidy caused by overexpression of the Aurora-and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58 : 4811 4816.
14. Kimura M., Matsuda Y., Yoshioka T., Okano Y. (1999) Cell cycle-dependent expression and centrosomal localization of a third human Aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 274 : 7334 7340.
15. Takahashi T., Futamura M., Yoshimi N., Sano J., Katada M., Takagi Y., Kimura M., Yoshioka T., Okano Y., Saji S. (2000) Centrosomal kinases, HsAIRk1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 91 : 1007 1014.
16. Keen N., Taylor S. (2004) Aurora-kinase inhibitors as anticancer agents. Nature Rev Cancer 4 : 927 936.
17. Mortlock A.A., Keen N.J., Jung F.H., Heron N.M., Foote K.M., Wilkinson R.W., Green S. (2005) Progress in the development of selective inhibitors of Aurora kinases. Curr Top Med Chem 5 : 807 821.
18. Fancelli D., Moll J. (2005) Inhibitors of Aurora kinases for the treatment of cancer. Expert Opin Ther Patents 15 : 1169 1182.
19. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M. et al. (2006) Validating Aurora B as an anti-cancer drug target. J Cell Sci 119 : 3664 3675.
20. Mahadevan D., Beeck S. (2007) Aurora kinase targeted therapeutics in oncology: past, present and future. Expert Opin Drug Discov 2 : 1011 1026.
21. Yang H., Burke T., Dempsey J., Diaz B., Collins E., Toth J., Beckmann R., Ye X. (2005) Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 579 : 3385 3391.
22. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., Taylor S.S. (2003) Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161 : 267 280.
23. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter R., Heckel A., Van Meel J., Rieder C.L., Peters J.-M. (2003) The small molecule Hesperadin reveals a role for Aurora B in connecting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161 : 281 294.
24. MurataHori M., Wang Y.L. (2002) The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis. Curr Biol 12 : 894 899.
25. Kallio M.J., McCleland M.L., Stukenberg P.T., Gorbsky G.J. (2002) Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr Biol 12 : 900 905.
26. Adams R.R., Maiato H., Earnshaw W.C., Carmena M. (2001) Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 153 : 865 880.
27. Giet R., Glover D.M. (2001) Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol 152 : 669 682.
28. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., Foster J.R. et al. (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13 : 3682 3688.
29. Moriarty K.J., Koblish H., Johnson D.L. Jr., Galemmo R.A. Jr. (2007) Progress in the development of agents to control the cell cycle. Top Med Chem 1 : 207 291.
30. Clement O.O., Mehl A.T. (2000) HipHop: pharmacophores based on multiple common-feature alignments. In : Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. La Jolla, CA : International University p. 69 84.
31. Li H., Sutter J., Hoffman R. (2000) HypoGen: an automated system for generating 3D predictive pharmacophore models. In : Güner O.F., editor. Pharmacophore Perception, Development, and Use in Drug Design. La Jolla, CA : International University p. 171 189.
32. Lipinski C.A., Lombardo F., Domiay B.W., Freeney P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J]. Adv Drug Deliv Rev 23 : 3 25.
33. Fancelli D., Moll J. Jr., Varasi M., Bravo R., Artico R., Berta D., Bindi S. et al. (2006) 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 49 : 7247 7251.
34. Vianello P. (2007) Aminopyridines: selective Aurora-A inhibitors. Expert Opin Ther Patents 17 : 255 261.
35. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M. et al. (2007) Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. PNAS 104 : 4106 4111.
36. Jung Fdr.H., Pasquet G., Brempt C.L.-vd., Lohmann J.-J.M., Warin N., Renaud F., Germain H., Savi C.D., Roberts N., Johnson T., Dousson C., Hill G.B., Mortlock A.A. (2006) Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 49 : 955 970.
37. Mortlock A.A., Foote K.M., Heron N.M., Jung F.H., Pasquet G., Lohmann J.-J.M., Warin N., Renaud F., Savi C.D. (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J Med Chem 50 : 2213 2224.
38. Foote K.M., Mortlock A.A., Heron N.M., Jung F.H., Hill G.B., Pasquet G., Brady M.C., Green S. (2008) Synthesis and SAR of 1-acetanilide-4- aminopyrazolesubstituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. Bioorg Med Chem Lett 18 : 1904 1909.
39. Brooks B.R., Brucolleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. (1983) CHARMM: a program for macromolecular energy, minimization and dynamics calculations. J Comput Chem 4 : 187 217.
40. Smellie A., Kahn S.D., Teig S.L. (1995) Analysis of conformational coverage. 1. Validation and estimation of coverage. J Chem Inf Comput Sci 35 : 285 294.
41. Smellie A., Kahn S.D., Teig S.L. (1995) Analysis of conformational coverage. 2. Applications of conformational models. J Chem Inf Comput Sci 35 : 295 304.
42. Smellie A., Teig S.L., Towbin P. (1995) Poling: promoting conformational coverage. J Comput Chem 16 : 171 187.
43. Debnath A.K. (2002) Pharmacophore mapping of a series of 2,4-diamino-5- deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J Med Chem 45 : 41 53.
44. Fischer R.A. (1966) The Design of Experiments. New York, USA : Hafner Publishing.
45. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalv I.N., Bonrne P.E. (2000) The protein data bank. Nucleic Acids Res 28 : 235 242.
46. Sessa F., Mapelli M., Ciferri C., Tarricone C., Areces L.B., Schneider T.R., Stukenberg P.T., Musacchio A. (2005) Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell 18 : 379 391.
47. Deng X.-Q., Wang H.-Y., Zhao Y.-L., Xiang M.-L., Jiang P.-D., Cao Z.-X., Zheng Y.-Z., Luo S.D., Yu L.-T., Wei Y.-Q., Yang S.-Y. (2008) Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors. Chem Biol Drug Des 71 : 533 539.
48. Zou J., Xie H.-Z., Yang S.-Y., Chen J.-J., Ren J.-X., Wei Y.-Q. (2008) Towards more accurate pharmacophore modeling: multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. J Mol Graph Model 27 : 430 438. doi
49. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graphics Modell 21 : 289 307.
50. Gehlhaar D.K., Verkhivker G.M., Rejto P.A., Sherman C.J., Fogel D.B., Fogel L.J. et al. (1995) Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol 2 : 317 324.
51. Jain A.N. (1996) Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. J Comput-Aided Mol Des 10 : 427 440.
52. Böhm H.J. (1994) The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J Comput -Aided Mol Des 8 : 243 256.
53. Böhm H.J. (1998) Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or three-dimensional database search programs. J Comput -Aided Mol Des 12 : 309 323.
54. Muegge I., Martin Y.C. (1999) A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem 42 : 791 804.
55. Clark R.D., Strizhev A., Leonard J.M., Blake J.F., Matthew J.B. (2002) Consensus scoring for ligand/protein interactions. J MolGraphics Modell 20 : 281 295.